RNATICS develops drugs based on short nucleic acid molecules, so-called oligonucleotides, that target disease-causing RNAs in tissue-resident macrophages.
This novel delivery mechanism enables access to organs that were previously inaccessible to nucleic acid therapies, thus opening up great therapeutic potential in many diseases.
We plan to start the first clinical trial (Phase I) of our lead candidate, RCS-21, for the treatment of fibrosing lung diseases following viral infections (e.g., COVID-19) in spring 2024.
RNATICS develops therapeutics based on RNA molecules, so called oligonucleotides, to target disease-causing RNAs in tissue resident macrophages, specific cells of the immune system. This novel way of delivery enables access to organs previously not accessible to nucleic acid therapy offering tremendous therapeutic opportunities for multiple diseases. We aim to start first-in-human clinical trials with our lead candidate, RCS-21, treating fibrotic lung injuries after viral infections (such as COVID-19) in early 2024.
